Bayer sets 2026 earnings call date, shares tracked against pharma peers

Bayer has confirmed the timing of its second-quarter 2026 earnings call, keeping investors focused on progress in its pharma pipeline and crop science restructuring as shares trade on Xetra alongside major healthcare peers.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 20:36.

Bayer (DE000BAY0017) has confirmed the timing of its second-quarter 2026 earnings call, keeping attention on its Xetra-listed shares as investors watch progress in pharma and crop science over the summer reporting season. The company continues to face close comparison with international healthcare peers such as Novartis and Sanofi, according to recent market commentary from German and Swiss brokers.

Next earnings date and guidance checkpoints

Per Bayer's investor relations calendar, the group plans to publish its second-quarter and half-year 2026 results and hold an earnings conference call in late July, a key checkpoint for management's ongoing efficiency and deleveraging program. Bayer's IR calendar for 2026 highlights quarterly results dates and capital markets events for the rest of the year, giving investors visibility on upcoming disclosures.

The upcoming call will likely revisit the company's guidance for 2026 group sales and core earnings, which were set out in previous quarterly reports and capital markets communication. Recent notes from analysts at Deutsche Bank and UBS have emphasized execution risk in Bayer's transformation program and the importance of meeting updated mid-term financial targets to support valuation relative to sector peers, as summarized in consensus data on platforms like MarketScreener and finanzen.net.

Analyst views and consensus on Bayer shares

Consensus data compiled by MarketScreener shows a mix of Buy, Hold and Sell ratings on Bayer shares, with a spread of price targets reflecting differing views on litigation exposure and growth in the pharmaceuticals and crop science divisions. MarketScreener's analyst summary on Bayer reports that a majority of covering analysts currently rate the stock as Hold or equivalent, while a minority maintain positive recommendations based on restructuring potential.

A recent commentary from Handelsblatt pointed out that international investors continue to compare Bayer with large-cap healthcare and agriscience names such as Novartis, Sanofi and Corteva, especially regarding balance sheet strength and litigation reserves. Handelsblatt analysis on Bayer's restructuring progress stresses that the upcoming earnings releases will be scrutinized for signs of margin improvement and cash generation, key to any debt reduction and potential portfolio moves.

What Bayer earns money with

Bayer generates revenue across three main divisions, with Pharmaceuticals focused on prescription medicines such as anticoagulant Xarelto and ophthalmology drug Eylea, Consumer Health offering brands in pain relief and allergy, and Crop Science providing seeds and crop protection products for global agriculture. Its diversified portfolio puts the group alongside peers like Novartis and Corteva in international investor comparisons.

Where Bayer stock trades today

Bayer shares most recently traded on Xetra at 28.40 euros as of 2026-06-29, 17:30, according to Deutsche Boerse data, keeping the stock within its recent range against the backdrop of ongoing restructuring and litigation discussions.

Bayer at a glance

• Company: Bayer AG
• ISIN: DE000BAY0017
• WKN: BAY001
• Ticker: BAYN
• Trading venue: Xetra
• Price (as of 2026-06-29, 17:30): 28.40 EUR
• Market cap: 28.5 billion EUR (as of 2026-06-29)
• Sector / industry: Healthcare and agriscience
• Index membership: DAX
• Next earnings date: 2026-07-25

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.